SCHEMBL7874510

SCHEMBL7874510

C[C@H](CCO)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL156431 1.00
SCHEMBL847297 1.00
SCHEMBL154669 0.97
Hydrochloric Acid SCHEMBL15796506 0.97
SCHEMBL5139179 0.87 GABRR1 (0.72)
SCHEMBL15228384 0.86 LTA4H (0.50)
SCHEMBL1859719 0.83
SCHEMBL422422 0.81 BLM (0.56)
SCHEMBL13554886 0.81 BLM (0.56)
SCHEMBL5472712 0.81 BLM (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11730748-B2 Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases MSD INTERNATIONAL GMBH (CH) 2023-08-22 US disclosed
US-11730748-B2 Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases MSD INTERNATIONAL GMBH (CH) 2023-08-22 US disclosed
US-20210205339-A1 CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES MSD INTERNATIONAL GMBH (CH) 2021-07-08 US disclosed
US-10766917-B2 Nucleotides for the treatment of cancer IDENIX PHARMACEUTICALS LLC (US) 2020-09-08 US disclosed
EP-3541825-A1 CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES Idenix Pharmaceuticals LLC. (US) 2019-09-25 EP disclosed
US-20180155385-A1 NUCLEOTIDES FOR THE TREATMENT OF CANCER IDENIX PHARMACEUTICALS LLC (US) 2018-06-07 US disclosed
WO-2018091542-A1 CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES IDENIX PHARMACEUTICALS LLC (US) 2018-05-24 WO disclosed
EP-3303359-A1 NUCLEOTIDES FOR THE TREATMENT OF CANCER Idenix Pharmaceuticals LLC (US) 2018-04-11 EP disclosed
WO-2016188943-A1 NUCLEOTIDES FOR THE TREATMENT OF CANCER IDENIX PHARMACEUTICALS LLC (US) 2016-12-01 WO disclosed
CN-102010403-A Total Synthesis of pladienolide B and pladienolide D EISAI R&D MAN CO LTD 2011-04-13 CN disclosed
CN-101282967-B Total synthesis of pladienolide b and pladienolide D EISAI R&D MAN CO LTD 2011-01-26 CN disclosed
CN-101282967-A Total synthesis of pladienolide b and pladienolide D EISAI R&D MAN CO LTD (JP) 2008-10-08 CN disclosed
EP-0855935-B1 CHIRAL SOLID CATALYST, ITS PREPARATION AND ITS USE FOR THE PRODUCTION OF SUBSTANTIALLY ENANTIOMERICALLY PURE PRODUCTS LEUVEN K U RES & DEV (BE) 2001-06-27 EP disclosed
US-5997840-A A BEA TOPOLOGY ZEOLITE AND A METAL-BINAP COMPLEX K.V. LEUVEN RESEARCH & DEVELOPMENT (BE) 1999-12-07 US disclosed
EP-0855935-A1 CHIRAL SOLID CATALYST, ITS PREPARATION AND ITS USE FOR THE PRODUCTION OF SUBSTANTIALLY ENANTIOMERICALLY PURE PRODUCTS K.U. Leuven Research & Development (BE) 1998-08-05 EP disclosed
WO-1997014500-A1 CHIRAL SOLID CATALYST, ITS PREPARATION AND ITS USE FOR THE PRODUCTION OF SUBSTANTIALLY ENANTIOMERICALLY PURE PRODUCTS K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 1997-04-24 WO disclosed